Originally developed by Metabolic Pharmaceuticals in Australia during the 1990s, this synthetic peptide was designed to harness growth hormones fat-mobilizing properties while avoiding the metabolic complications associated with full-length GH therapy
The molecule was developed by the Australian pharmaceutical company Metabolic Pharmaceuticals (in collaboration with Monash University) and advanced through Phase I safety trials and a Phase IIb obesity efficacy trial enrolling approximately 900 participants in total
A 2019 randomized controlled trial of lipotropic injections (methionine, inositol, choline, B12) versus saline placebo in 120 participants on ad libitum diets found 0.8 kg (1.76 pounds) difference at 12 weeks, not statistically significant (p=0.18) (Karbalay-Doust et al., Journal of Research in Medical Sciences , 2019)
Treatment Frequency and Protocol: B12 injection frequency varies based on deficiency severity and individual response
However, cancer patients usually benefit from vitamin B12 supplementation
Starting at a lower dose allows tissues to respond without overstimulation, then the higher dose in Phase 2 extends and deepens that response